Journal article
School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo
LW Doyle, PJ Anderson, R Haslam, KJ Lee, C Crowther, B Darlow, N Austin, N French, C Campbell, E Carse, M Hayes, J Harding, C McKinlay, C Bevan, A De Paoli, L Sutton, I Rieger, C Wocadlo, P Colditz, M Pritchard Show all
JAMA Journal of the American Medical Association | Published : 2014
Abstract
IMPORTANCE: Antenatal magnesium sulfate given to pregnant women at imminent risk of very preterm delivery reduces the risk of cerebral palsy in early childhood, although its effects into school age have not been reported from randomized trials. OBJECTIVE: To determine the association between exposure to antenatal magnesium sulfate and neurological, cognitive, academic, and behavioral outcomes at school age. DESIGN, SETTING, AND PARTICIPANTS: The ACTOMgSO4 was a randomized clinical trial conducted in 16 centers in Australia and New Zealand, comparing magnesium sulfate with placebo given to pregnant women (n = 535 magnesium; n = 527 placebo) for whom imminent birth was planned or expected befo..
View full abstractGrants
Awarded by National Health and Medical Research Council Australia
Funding Acknowledgements
This study was funded by a project grant (350326) from the National Health and Medical Research Council Australia and the Victorian Government's Operational Infrastructure Support Program.